In a filing, Avidity Biosciences Inc revealed its Chief Medical Officer Hughes Steven George unloaded Company’s shares for reported $0.11 million on Oct 22 ’25. In the deal valued at $47.54 per share,2,209 shares were sold. As a result of this transaction, Hughes Steven George now holds 38,867 shares worth roughly $2.71 million.
Then, McCarthy Teresa sold 20,000 shares, generating $1,003,058 in total proceeds. Upon selling the shares at $50.15, the Chief Human Resources Officer now owns 97,130 shares.
Before that, Mosbrooker Eric sold 6,562 shares. Avidity Biosciences Inc shares valued at $297,771 were divested by the Chief Commercial Officer at a price of $45.38 per share. As a result of the transaction, Mosbrooker Eric now holds 55,000 shares, worth roughly $3.84 million.
Roth Capital initiated its Avidity Biosciences Inc [RNA] rating to a Buy in a research note published on September 17, 2025; the price target was $62. Bernstein began covering RNA with “an Outperform” recommendation on June 24, 2025. Wolfe Research started covering the stock on June 17, 2025. It rated RNA as “an Outperform”.
Price Performance Review of RNA
On Tuesday, Avidity Biosciences Inc [NASDAQ:RNA] saw its stock jump 0.04% to $69.83. Over the last five days, the stock has lost -0.14%. Avidity Biosciences Inc shares have risen nearly 65.24% since the year began. Nevertheless, the stocks have risen 140.13% over the past one year. While a 52-week high of $70.51 was reached on 10/27/25, a 52-week low of $21.51 was recorded on 04/09/25.
Levels Of Support And Resistance For RNA Stock
The 24-hour chart illustrates a support level at 69.77, which if violated will result in even more drops to 69.71. On the upside, there is a resistance level at 69.88. A further resistance level may holdings at 69.93.
How much short interest is there in Avidity Biosciences Inc?
A steep rise in short interest was recorded in Avidity Biosciences Inc stocks on 2025-10-15, dropping by -2.21 million shares to a total of 20.03 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 22.24 million shares. There was a decline of -11.06%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 11, 2025 when Raymond James began covering the stock and recommended ‘”a Strong buy”‘ rating along with a $65 price target.
